Are These Stocks Worth Taking A Chance On? Comstock Resources Inc (CRK), Novovax Inc (NVAX) and PDL BioPharma Inc (PDLI)

Posted by admin April 8, 2015 0 Comment 928 views

New York, NY – GDP INSIDER  –  04/08/2015.

This article discusses three companies: Comstock Resources Inc (NYSE:CRK), Novovax Inc (NASDAQ:NVAX) and PDL BioPharma Inc (NASDAQ:PDLI)

Comstock Resources Inc(NYSE:CRK) continued to gain yesterday with the shares closing up 2.05% or $0.09 at $4.476 with more than 3.67 million shares trading hands compared with its 30 day average trading volume of 2.75 million. The Texas based energy company currently situated 84.51% below its 52 week high of $28.86. The stock has lost 80.37% over the last 52 weeks and is currently one of the worst performers in the oil and gas sector, but with a one year target estimate of $5.96 there may be significant upside potential.

Are Comstock Resources Inc Shares Undervalued? Read Our Free CRK Analysis To Decide.

Novovax Inc (NASDAQ:NVAX) bounced back yesterday to close up 2.56% or $0.20 on light trading volume of 3.08 million, compared to its 30 day average trading volume of 5.60 million. The infectious disease clinical stage biopharmaceutical company is enjoying solid gains so far this year, with the share price up 95.84% as investors move out of oil and related commodities into the medical research sector. The RSI of 41.87 indicates the stock is not undervalued, the MFI of 38.42 shows the money is flowing in the right direction, making it a hold at best for now.

Is Novovax Inc’s Current Trend A True Indicator Of Its Value? Get The Complete Picture with Free NVAX Analysis.

PDL BioPharma Inc (NASDAQ:PDLI) reversed its recent upward trend yesterday with the stock declining 0.50% or $0.03 to finish the day at a closing price of $6.97 on light trading volume of 3.64 million, compared to its 30 day average trading volume of 4.53 million shares. The US-based biotech company currently stands at a positive return on assets of 34.70%, return on equity of 94.70% and return on investment of 39.60%. With EPS of $1.82, price to earnings ratio of 3.83 and one year target price estimate of $7.50, PDL BioPharma Inc is a solid hold with a view to buy.

Can PDL BioPharma Inc Reverse Its Current Downward Trend? Make A Smart Investment Move With Our Free PDLI Analysis.

About UltimateStockAlerts provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.

UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure:  UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit website, for complete risks and disclosures.

Write Your Comment